Cynthia Lavoie
Director/Board Member at PROFOUND MEDICAL CORP.
Net worth: 48 180 $ as of 29/04/2024
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
David G. Lowe | M | 67 |
AllosteRx Capital Management (Canada), Inc.
Delta TpX, Inc.
Delta TpX, Inc. Pharmaceuticals: OtherHealth Technology Delta TpX, Inc. develops oncology therapeutics. The American company was founded by Everett Stone, Aaron Schuchart, Cynthia Lavoie, David G. Lowe. David G. Lowe has been the CEO since incorporation. | - |
Rashed Dewan | M | 56 | 9 years | |
Everett Stone | M | - |
Delta TpX, Inc.
Delta TpX, Inc. Pharmaceuticals: OtherHealth Technology Delta TpX, Inc. develops oncology therapeutics. The American company was founded by Everett Stone, Aaron Schuchart, Cynthia Lavoie, David G. Lowe. David G. Lowe has been the CEO since incorporation. | - |
Arun Menawat | M | 69 | 9 years | |
Jean Bourgouin | M | - |
Kaneq Bioscience Ltd.
Kaneq Bioscience Ltd. BiotechnologyHealth Technology Kaneq Bioscience Ltd. operates as a biotechnology company focuses on developing treatments for type 2 diabetes. The firm develops a protein tyrosine phosphatase1B inhibitor for treating type 2 diabetes mellitus. The company was founded by Jean Bourgouin on October 19, 2012 and is headquartered in Montreal, Canada. | 12 years |
Jacques Fernand Cornet | M | 67 | - | |
Aaron Schuchart | M | 59 |
Delta TpX, Inc.
Delta TpX, Inc. Pharmaceuticals: OtherHealth Technology Delta TpX, Inc. develops oncology therapeutics. The American company was founded by Everett Stone, Aaron Schuchart, Cynthia Lavoie, David G. Lowe. David G. Lowe has been the CEO since incorporation. | - |
Philippe Tessier | M | - |
Kaneq Bioscience Ltd.
Kaneq Bioscience Ltd. BiotechnologyHealth Technology Kaneq Bioscience Ltd. operates as a biotechnology company focuses on developing treatments for type 2 diabetes. The firm develops a protein tyrosine phosphatase1B inhibitor for treating type 2 diabetes mellitus. The company was founded by Jean Bourgouin on October 19, 2012 and is headquartered in Montreal, Canada. | - |
Mathieu Burtnyk | M | 42 | 13 years | |
Kris Shah | M | 63 | 2 years | |
Arthur Rosenthal | M | 77 | 6 years | |
Hartmut Warnken | M | - | 9 years | |
Brian Robert Ellacott | M | 67 | 6 years | |
Luc Marengère | M | 59 |
TVM Life Science Management, Inc.
Cytochroma, Inc.
Cytochroma, Inc. Pharmaceuticals: MajorHealth Technology Cytochroma, Inc. is a clinical-stage specialty pharmaceutical company. It develops and markets prescription products for the prevention of vitamin D insufficiency. The firm specializes in pharmaceutical products to treat and prevent secondary hyperparathyroidism associated with chronic kidney disease. The company was founded by Martin J. Petkovich in 1996 and is headquartered in Markham, Canada. | 12 years |
Raf Hofstein | M | 74 |
Fibrocor Therapeutics LP
Fibrocor Therapeutics LP Miscellaneous Commercial ServicesCommercial Services Fibrocor Therapeutics LP is a privately held Canadian drug discovery company that is pioneering the use of tissue-specific therapeutics in the field of precision medicine, particularly in fibrosis. The company is based in Toronto, Canada. The company aims to improve the lives of patients by delivering transformative treatments that tackle the root causes of fibrosis, leading to better outcomes and enhanced quality of life. Fibrocor leverages its extensive expertise and one of the largest patient-derived clinically annotated biorepositories of fibrotic tissue to refine and validate therapeutic candidates, ensuring they meet the highest standards of efficacy and safety. | - |
Franz Hefti | M | 76 |
FAAH Pharma, Inc.
FAAH Pharma, Inc. BiotechnologyHealth Technology FAAH Pharma, Inc. operates as a project-focused company developing a clinical asset initially for postherpetic neuralgia. The company was founded on June 26, 2014 and is headquartered in Montreal, Canada. | - |
Jochen Knolle | M | 74 |
Anchor Therapeutics, Inc.
Anchor Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Anchor Therapeutics, Inc. designs and develops peptide modulators of G protein-coupled receptors (GPCRs). The firm engages in developing and licensing pepducin technology as a research tool for drug development; and pepducin drug candidates and novel molecules that are intended for targeting GPCR to allosterically modulate GPCR signaling. Its pepducin lipopeptides are designed to allosterically modulate internal cell signaling via specific interactions with intracellular GPCR domains. The company also focuses on developing its pepducin technology for creating new treatment options for regenerative medicine, diabetes, inflammation, and cancer. Anchor Therapeutics was founded by Thomas J. McMurry and Athan Kuliopulos in 2006 and is headquartered in Cambridge, MA. | - |
Andre Hoekema | M | 67 |
Fibrocor Therapeutics LP
Fibrocor Therapeutics LP Miscellaneous Commercial ServicesCommercial Services Fibrocor Therapeutics LP is a privately held Canadian drug discovery company that is pioneering the use of tissue-specific therapeutics in the field of precision medicine, particularly in fibrosis. The company is based in Toronto, Canada. The company aims to improve the lives of patients by delivering transformative treatments that tackle the root causes of fibrosis, leading to better outcomes and enhanced quality of life. Fibrocor leverages its extensive expertise and one of the largest patient-derived clinically annotated biorepositories of fibrotic tissue to refine and validate therapeutic candidates, ensuring they meet the highest standards of efficacy and safety. | - |
Gail Farfel | M | 60 |
FAAH Pharma, Inc.
FAAH Pharma, Inc. BiotechnologyHealth Technology FAAH Pharma, Inc. operates as a project-focused company developing a clinical asset initially for postherpetic neuralgia. The company was founded on June 26, 2014 and is headquartered in Montreal, Canada. | - |
Murielle Lortie | F | 54 | 4 years | |
Stephen Kilmer | M | - | - | |
Michael May | M | 56 |
CCRM Enterprises Inc
| - |
Brendan M. O'Leary | M | 52 |
AllosteRx Capital Management (Canada), Inc.
| - |
Gosse Bote Bruinsma | M | 69 |
FAAH Pharma, Inc.
FAAH Pharma, Inc. BiotechnologyHealth Technology FAAH Pharma, Inc. operates as a project-focused company developing a clinical asset initially for postherpetic neuralgia. The company was founded on June 26, 2014 and is headquartered in Montreal, Canada. | - |
Valentina Agostina | M | - |
TVM Life Science Management, Inc.
| 4 years |
Michael Berendt | M | 75 |
Anchor Therapeutics, Inc.
Anchor Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Anchor Therapeutics, Inc. designs and develops peptide modulators of G protein-coupled receptors (GPCRs). The firm engages in developing and licensing pepducin technology as a research tool for drug development; and pepducin drug candidates and novel molecules that are intended for targeting GPCR to allosterically modulate GPCR signaling. Its pepducin lipopeptides are designed to allosterically modulate internal cell signaling via specific interactions with intracellular GPCR domains. The company also focuses on developing its pepducin technology for creating new treatment options for regenerative medicine, diabetes, inflammation, and cancer. Anchor Therapeutics was founded by Thomas J. McMurry and Athan Kuliopulos in 2006 and is headquartered in Cambridge, MA. | - |
Erin Overstreet | M | - |
Delta TpX, Inc.
Delta TpX, Inc. Pharmaceuticals: OtherHealth Technology Delta TpX, Inc. develops oncology therapeutics. The American company was founded by Everett Stone, Aaron Schuchart, Cynthia Lavoie, David G. Lowe. David G. Lowe has been the CEO since incorporation. | - |
Abbey Goodman | F | 41 | - |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Ken Galbraith | M | 61 | 6 years | |
Jean-François Pariseau | M | 54 | 7 years | |
Aaron Davidson | M | 55 | 4 years | |
Lily Lam | F | - |
Cytochroma, Inc.
Cytochroma, Inc. Pharmaceuticals: MajorHealth Technology Cytochroma, Inc. is a clinical-stage specialty pharmaceutical company. It develops and markets prescription products for the prevention of vitamin D insufficiency. The firm specializes in pharmaceutical products to treat and prevent secondary hyperparathyroidism associated with chronic kidney disease. The company was founded by Martin J. Petkovich in 1996 and is headquartered in Markham, Canada. | - |
Seiichi Kiso | M | - |
Cytochroma, Inc.
Cytochroma, Inc. Pharmaceuticals: MajorHealth Technology Cytochroma, Inc. is a clinical-stage specialty pharmaceutical company. It develops and markets prescription products for the prevention of vitamin D insufficiency. The firm specializes in pharmaceutical products to treat and prevent secondary hyperparathyroidism associated with chronic kidney disease. The company was founded by Martin J. Petkovich in 1996 and is headquartered in Markham, Canada. | - |
Osamu Otani | M | - |
Cytochroma, Inc.
Cytochroma, Inc. Pharmaceuticals: MajorHealth Technology Cytochroma, Inc. is a clinical-stage specialty pharmaceutical company. It develops and markets prescription products for the prevention of vitamin D insufficiency. The firm specializes in pharmaceutical products to treat and prevent secondary hyperparathyroidism associated with chronic kidney disease. The company was founded by Martin J. Petkovich in 1996 and is headquartered in Markham, Canada. | - |
Kenneth Knudson | M | - | - | |
Steve Forte | M | 45 | 2 years |
Statistics
Country | Connections | % of total |
---|---|---|
Canada | 31 | 86.11% |
United States | 6 | 16.67% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Cynthia Lavoie
- Personal Network